Introduction
Rituximab is a chimeric human-mouse monoclonal antibody that reacts specifically with the CD20 antigen present on most B-cells and is used in the treatment of hematological malignancies and autoimmune diseases. Rituximab gives rapid sustained depletion of premature and mature B-cells that return to pre-treatment level generally within 12 months. 1 Rituximab can lead to a state of immunosuppression through B-cell depletion, but also through the development of late onset neutropenia (LON) and hypogammaglobulinemia. 1 The reported incidence of LON secondary to rituximab in the treatment of hematological malignancies is between 3 and 27% and resulting infections are neither frequent nor severe. 2 Reports of LON in the treatment of autoimmune diseases are scarce. 3, 4 Herein, we review eight cases of LON secondary to rituximab from a single center and we aim to identify both patients' and LON characteristics in a rheumatologic setting.
Method
LON was defined as grade III-IV neutropenia (absolute neutrophil count under 1.0 Â 10 9 /l) according to the National Cancer Institute Common Toxicity Criteria occurring 4 weeks after the last rituximab administration. 2, 5, 6 Using this case definition, we identified eight patients since 2006 in our center with LON secondary to rituximab. They represent 5.8% of the total number of patients receiving rituximab. Two additional patients experienced early neutropenia occurring 2 weeks after the first rituximab administration and were not included.
All patients were initially treated according to the rheumatoid arthritis (RA) protocol with two rituximab infusions of 1000 mg each, 2 weeks apart. Patients then received maintenance therapy either every 6 months (1000 mg) or every 9-12 months (1000 mg Â 2, 2 weeks apart). Rituximab was either added to previous immunosuppressive treatment or given in combination with methotrexate.
Patient records were reviewed retrospectively and data on comorbidities, previous immunosuppressive treatments, infections, disease duration prior to rituximab administration, the cumulative rituximab dose, the time interval between the last rituximab infusion and LON and the duration of neutropenia were extracted. Immunological parameters, such as immunoglobulin (Ig) subclass levels, CD4 count (ratio CD4/CD8) and autoantibody titers prior to, during and following LON development were also recorded.
B-cells recovery was defined as an absolute B-cells count 50.01 Â 10 9 /l when complete B-cells depletion was lost.
Results

Patients' characteristics
The underlying disease was granulomatosis with polyangiitis (GPA earlier called Wegener's granulomatosis) in five patients; the others patients had type 1 cryoglobulinemia, juvenile idiopathic arthritis and anti-citrullinated peptide antibody positive RA ( Table 1 ). The male to female ratio was 1; but all men had GPA. Rituximab was administered because patients were considered to have complicated disease that was refractory to our standard immunosuppressive treatment protocols. Three GPA patients received renal transplants, two patients prior to and one after the initiation of rituximab therapy. Two patients had hematological malignancies: one patient was diagnosed with non-Hodgkin's lymphoma prior to rituximab and one with smoldering myeloma 6 months after rituximab therapy.
The median duration of the disease prior to rituximab treatment was 156 months (75-408 months). The daily median dose of prednisolone was 3.75 mg (0-15 mg daily) and the median number of immunosuppressive drugs used prior to rituximab was 4.5 (2-7). The median cumulative cyclophosphamide dose in GPA patients was 23.7 g (2.4-250 g). Five patients had previous episodes of leucopenia prior to rituximab and during the use of cyclosporin A, cyclophosphamide, sulfasalazine and azathioprine for two patients.
LON characteristics
LON appeared after a median interval of 23 weeks (7-48 weeks) following rituximab administration ( Table 2 ). The median absolute neutrophil count was 0.2 Â 10 9 /l and neutrophils were undetectable in three patients. Neutropenia recovered after a median of 6.5 days (3-270 days). B-cells recovery came shortly after the onset of neutropenia in two patients 1 and 2 months, respectively (B-cells counts 0.05 and 0.3 Â 10 9 /l, respectively). Four patients were symptomatic during LON: fever, diarrhea and oral ulcers were the most common symptoms. Candida albicans from an oral swab and Clostridium difficile from feces were identified in one patient each. A third patient was hospitalized for severe Staphylococcus aureus pneumonia in the intensive therapy unit complicated afterwards with C. albicans and Stenotrophomonas maltophilia, secondary to an obstructed bronchial stent due to GPA damage. Four patients received intravenous antibiotics, but none were treated with the granulocyte colony-stimulating factor during LON.
Immunological abnormalities
The relation between LON and immunological
abnormalities is shown in Table 3 . Significant reduction in all Ig subclasses was seen at LON. Seven patients had some immunological abnormality prior to rituximab: four patients had Ig class deficiency, five patients had low CD4. At the onset of neutropenia, six patients had both lower IgM level (one patient had undetectable level) and lower IgG-three patients also had deficiency in IgA. After the onset of neutropenia, six patients had low IgM levels, two patients had undetectable IgM levels. Both IgM and IgG levels were equivalent at the time of LON and at last visit despite discontinuation of rituximab in seven patients. 2. Three of five GPA patients had positive anti-neutrophil cytoplasmic antibody (ANCA) at rituximab initiation; ANCA disappeared in two patients although one still had ANCA positive (although with decreasing titer) by the time of LON. The two ANCA-negative patients also responded to rituximab and are in remission with negative ANCA. 
Outcome
Six patients received maintenance therapy (rechallenge) with rituximab after a median of 2 months (1-5 months) after the onset of neutropenia but no recurrence of neutropenia was observed ( Table 2) . One patient experienced an unexplained recurrent neutropenia 6 weeks after resolution of the first LON episode without being challenged again with rituximab. Two patients were not rechallenged with rituximab because of hypogammaglobulinemia and low CD4 count. One patient is currently receiving intravenous Igs and the other is closely monitored with improving levels of Igs-as well as slow recovery of B-cells (B-cells count 0.04 Â 10 9 /l)-29 months after the last rituximab administration. At last visit-a median of 30.5 months (12-48 months) after rituximab initiation and a median of 16 months (4-44 months) after LON, seven patients have discontinued rituximab. One patient developed severe hypogammaglobulinemia during rituximab maintenance therapy. One patient had no clinical response to rituximab despite hypogammaglobulinemia. One patient developed colitis attributed to rituximab. One patient had maintained remission following kidney transplantation. One GPA patient died of sepsis without an identifiable cause 24 months after LON and after being diagnosed with a myelodysplastic syndrome; this patient had sustained low CD4 with a nadir of 0.05, panhypogammaglobulinemia and had received a total of 250 g of cyclophosphamide.
Discussion
This case review showed that LON occurs in 6% of patients with a heterogeneous group of rheumatic diseases, $5 months after rituximab administration. This is comparable with the occurrence of LON in hematological malignancies, where it seems to coincide with the time of B-cell recovery. 2 The association of LON with B-cells recovery is illustrated by the two patients achieving B-cells recovery 1 and 2 months after LON. It has been hypothesized that LON is caused by perturbation of the granulocyte homeostasis during B-cell recovery as stromalderived factor-1 level regulates granulocytes egress and is required for B-cells lymphopoiesis. 5, 6 Rechallenge with rituximab has not led to recurrent LON in our patients; the one patient with LON recurrence 6 weeks after the first episode without rechallenge suggests a subacute break down of the homeostasis with either maturation arrest or hematopoietic stem cell competition. 7 The majority of patients in our analysis suffered from GPA that may have led to some important biases. The use of aggressive immunosuppressive therapy including methotrexate, azathioprine and cyclophosphamide in refractory GPA and its complications (three patients with renal transplantation and one patient with bronchial stenting) are likely to have contributed to the risk of LON development. This is in agreement with the increased risk of rituximab-induced LON in patients after autologous stem cell transplantation, patients with acquired immunodeficiency syndrome-related lymphoma, patients treated with purine analogs and patients that received previous cytotoxic treatment. 2 Similar to hematological patients, 2 LON usually has a rapid recovery without the use of colony-stimulating factors and does not seem to increase the risk for serious infection in our patients even though four out of eight patients had concomitant infection with LON. This is in disagreement with the study of Tesfa et al. 4 that concludes that LON is a significant adverse event associated with severe infections . Our patients seem to differ as they received a lower daily dose of prednisolone (3.75 vs. 20 mg) and none was treated concomitantly with cyclophosphamide (zero vs. four patients). The only patient (Case 5) needing intensive care for severe pneumonia had LON and concomitant sustained panhypogammaglobulinemia including undetectable level of IgM. Sustained cellular and humoral immunodeficiency due to myelodysplasia contributed to sepsis and death in another patient (Case 8) 24 months after LON.
It has recently been suggested that rituximabinduced LON is a good prognostic indicator in lymphoproliferative disorders. 8 Likewise, our patients developing LON had a good clinical response to rituximab treatment (except for Case 1), but in the majority of LON patients rituximab was discontinued because of side effects. While new-onset hypogammaglobulinemia affects <10% of RA patients after the first course of rituximab; 9 iterative rituximab treatment has led to a continuous decrease of Igs levels in most of our LON patients resulting in sustained hypogammaglobulinemia and contributing to the discontinuation of rituximab in at least four patients. Tesfa et al. 4 found that LON patients had longer lasting and more severe B-cells depletion compared with controls, which would increase the risk for developing a sustained hypogammaglobulinemia. Thus, a sustained hypogammaglobulinemia either induced or aggravated by rituximab (as renal failure, organ transplantation, use of prednisolone can also induce hypogammaglobulinemia) seems to heighten the risk of infections in LON patients. 10, 11 These data reflect the continuing challenge in treating rheumatologic patients without overtreating them; while LON does not seem to pose a substantial risk in itself, the question remains which lower limits of Ig levels are safe for our patients following rituximab treatment.
